A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs ABBV-155 (Primary) ; Docetaxel; Paclitaxel
- Indications Breast cancer; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors AbbVie
- 31 Oct 2019 Planned number of patients changed from 125 to 152.
- 31 Oct 2019 Planned End Date changed from 29 Apr 2021 to 30 Dec 2021.
- 31 Oct 2019 Planned primary completion date changed from 29 Apr 2021 to 30 Dec 2021.